Addressing the challenge for well informed and consistent reimbursement decisions: The case for reference models

Research output: Contribution to journalEditorial

14 Citations (Scopus)

Abstract

Editorial
In the context of ever-increasing healthcare expenditures and resource-limited health services, the comparative analysis of costs and benefits of competing healthcare technologies (e.g. pharmaceuticals) is essential to support public funding decisions. Australia has been at the forefront of the integration of economic evidence with reimbursement decisions to fund new pharmaceutical products through a national-level body, the Pharmaceutical Benefits Advisory Committee (PBAC). Pharmaceutical companies submit applications to have their products considered for reimbursement. The PBAC recommendations form the basis of Australian Government decisions about public funding and listing of medicines on the Pharmaceutical Benefits Scheme. The UK National Institute for Health and Clinical Excellence (NICE), amongst others, has adopted guidelines to use economic evidence for reimbursement decision processes.
Original languageEnglish
Pages (from-to)823-825
Number of pages3
JournalPharmacoeconomics
Volume29
Issue number10
DOIs
Publication statusPublished - Oct 2011

Keywords

  • healthcare costs
  • Pharmaceutical Benefits Schedule (PBS)
  • pharmaceutical funding support
  • Decision analysis model

Fingerprint Dive into the research topics of 'Addressing the challenge for well informed and consistent reimbursement decisions: The case for reference models'. Together they form a unique fingerprint.

  • Cite this